Authors

Latest:

Dr. Krug on Intra-Pleural Administration of GL-ONC1 in Patients With Malignant Pleural Effusion

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

Lee S. Schwartzberg, MD

Latest:

Dr. Schwartzberg on Emerging Biomarkers in NSCLC

Lee S. Schwartzberg, MD, FACP, chief and professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, medical director, West Clinic, executive director, West Cancer Center, discusses several emerging biomarkers in non–small cell lung cancer (NSCLC).

Lee S. Schwartzberg, MD, FACP

Latest:

Future Directions in HR+ Breast Cancer Management

Lee Schwartzberg, MD, FACP, and Mark Pegram, MD, highlight exciting prognostic technology on the horizon for HR+ breast cancer.

Lee S. Schwartzberg, MD, FACP, University of Tennessee Health Science Center

Lee S. Schwartzberg, MD, University of Tennessee Health Science Center

Lee Schwartzberg, MD, FACP, The University of Texas Health Science Center

Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute

Latest:

Dr. Schwartzberg on the Use of Myriad Genomic Testing in Cancer Care

Lee S. Schwartzberg, MD, FACP, discusses the utilization of genomics in cancer care.

Lee Schwartzberg, MD, FACP, West Cancer Center SAMPLE KOL NAME, institution

Leena Gandhi, MD, PhD

Latest:

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Lei Chen, MD, PhD

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Leif Bergsagel, MD

Latest:

Dr. Bergsagel on Treatment Options for Relapsed/Refractory Myeloma

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.

Leigh A. Neumayer, MD

Latest:

Dr. Neumayer Discusses the POWER PIINC Trial

Leigh A. Neumayer, MD, discusses the POWER PIINC trial, a study to measure the preoperative window of endocrine therapy.

Leigha Senter, MS, LGC

Latest:

Biomarker Research in Ovarian Cancer

Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.

Leisha A. Emens, MD, PhD

Latest:

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Leo Gordon, MD, Northwestern Memorial Hospital

Leo I. Gordon, MD

Latest:

Dr Gordon on Managing Toxicities Associated With Liso-Cel in MCL

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Leo I. Gordon, MD, FACP, Robert H. Lurie Comprehensive Cancer Center

Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Leonard G. Gomella, MD

Latest:

Dr. Gomella on Novel Biomarker Research in Prostate Cancer

Leonard G. Gomella, MD, discusses ongoing studies evaluating novel biomarkers in prostate cancer.

Leonard G. Gomella, MD, Jefferson Kimmel